School of Science, Shandong Jiaotong University, Jinan, China.
SAR QSAR Environ Res. 2021 Apr;32(4):293-315. doi: 10.1080/1062936X.2021.1891966. Epub 2021 Mar 3.
Adipocyte fatty-acid binding protein (A-FABP) plays a central role in many aspects of metabolic diseases. It is an important target in drug design for treatment of FABP-related diseases. In this study, molecular dynamics (MD) simulations followed by calculations of molecular mechanics generalized Born surface area (MM-GBSA) and principal components analysis (PCA) were implemented to decipher molecular mechanism correlating with binding of inhibitors 57Q, 57P and L96 to A-FABP. The results show that van der Waals interactions are the leading factors to control associations of 57Q, 57P, and L96 with A-FABP, which reveals an energetic basis for designing of clinically available inhibitors towards A-FABP. The information from PCA and cross-correlation analysis rationally unveils that inhibitor bindings affect conformational changes of A-FABP and change relative movements between residues. Decomposition of binding affinity into contributions of individual residues not only detects hot spots of inhibitor/A-FABP binding but also shows that polar interactions of the positively charged residue Arg126 with three inhibitors provide a significant contribution for stabilization of the inhibitor/A-FABP bindings. Furthermore, the binding strength of L96 to residues Ser55, Phe57 and Lys58 are stronger than that of inhibitors 57Q and 57P to these residues.
脂肪细胞脂肪酸结合蛋白(A-FABP)在代谢性疾病的许多方面发挥着核心作用。它是治疗与 FABP 相关疾病的药物设计中的重要靶点。在这项研究中,我们实施了分子动力学(MD)模拟,随后进行了分子力学广义 Born 表面积(MM-GBSA)和主成分分析(PCA)的计算,以破译与抑制剂 57Q、57P 和 L96 与 A-FABP 结合相关的分子机制。结果表明,范德华相互作用是控制 57Q、57P 和 L96 与 A-FABP 结合的主要因素,这为设计针对 A-FABP 的临床可用抑制剂提供了能量基础。PCA 和互相关分析的信息合理地揭示了抑制剂结合会影响 A-FABP 的构象变化,并改变残基之间的相对运动。将结合亲和力分解为单个残基的贡献不仅可以检测抑制剂/A-FABP 结合的热点,还表明带正电荷的残基 Arg126 与三种抑制剂的极性相互作用为抑制剂/A-FABP 结合的稳定提供了重要贡献。此外,L96 与残基 Ser55、Phe57 和 Lys58 的结合强度强于抑制剂 57Q 和 57P 与这些残基的结合强度。